Detalles de la búsqueda
1.
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.
Cell
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754421
2.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
N Engl J Med
; 388(23): 2159-2170, 2023 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36972022
3.
Top advances of the year: Uterine cancer.
Cancer
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38620054
4.
Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
Gynecol Oncol
; 187: 241-248, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833993
5.
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Int J Gynecol Cancer
; 33(4): 504-513, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36750267
6.
Immunotherapy treatment landscape for patients with endometrial cancer: current evidence and future opportunities.
Clin Adv Hematol Oncol
; 21(1): 27-34, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36638353
7.
Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer.
J Comput Assist Tomogr
; 46(5): 707-715, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35995483
8.
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Oncologist
; 26(4): e530-e536, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528846
9.
PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.
N Engl J Med
; 389(9): 867-868, 2023 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646696
10.
Charting a professional course for academic gynecologic oncology mentors.
Gynecol Oncol
; 160(1): 265-270, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33131903
11.
Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.
Gynecol Oncol
; 163(2): 299-304, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34561099
12.
Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation.
Gynecol Oncol
; 160(3): 721-728, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33342621
13.
Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials.
Gynecol Oncol
; 162(2): 389-393, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34099315
14.
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Gynecol Oncol
; 161(1): 25-33, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33293046
15.
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
Gynecol Oncol
; 162(1): 203-209, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33722417
16.
Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol.
Am J Obstet Gynecol
; 225(4): 442.e1-442.e10, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34245679
17.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34593565
18.
Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
J Obstet Gynaecol
; 41(6): 956-961, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33228421
19.
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Gynecol Oncol
; 159(1): 8-12, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32778410
20.
Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial.
Gynecol Oncol
; 157(2): 494-499, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32081462